• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Enterotoxins can support CAR T cells against solid tumors.肠毒素可支持 CAR T 细胞对抗实体瘤。
Proc Natl Acad Sci U S A. 2019 Dec 10;116(50):25229-25235. doi: 10.1073/pnas.1904618116. Epub 2019 Nov 25.
2
Inducible Activation of MyD88 and CD40 in CAR T Cells Results in Controllable and Potent Antitumor Activity in Preclinical Solid Tumor Models.嵌合抗原受体 T 细胞中 MyD88 和 CD40 的诱导激活可导致临床前实体瘤模型中可控且有效的抗肿瘤活性。
Cancer Discov. 2017 Nov;7(11):1306-1319. doi: 10.1158/2159-8290.CD-17-0263. Epub 2017 Aug 11.
3
Intercellular adhesion molecule-1 and leukocyte function-associated antigen-3 provide costimulation for superantigen-induced T lymphocyte proliferation in the absence of a specific presenting molecule.细胞间黏附分子-1和白细胞功能相关抗原-3在缺乏特异性呈递分子的情况下为超抗原诱导的T淋巴细胞增殖提供共刺激。
J Immunol. 1998 Jan 15;160(2):615-23.
4
Enhanced Cancer Immunotherapy by Chimeric Antigen Receptor-Modified T Cells Engineered to Secrete Checkpoint Inhibitors.嵌合抗原受体修饰的 T 细胞分泌检查点抑制剂增强癌症免疫治疗。
Clin Cancer Res. 2017 Nov 15;23(22):6982-6992. doi: 10.1158/1078-0432.CCR-17-0867. Epub 2017 Sep 14.
5
Constitutively active MyD88/CD40 costimulation enhances expansion and efficacy of chimeric antigen receptor T cells targeting hematological malignancies.组成性激活的 MyD88/CD40 共刺激增强了针对血液恶性肿瘤的嵌合抗原受体 T 细胞的扩增和疗效。
Leukemia. 2019 Sep;33(9):2195-2207. doi: 10.1038/s41375-019-0417-9. Epub 2019 Feb 28.
6
A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects.一种新型嵌合抗原受体,包含 JAK-STAT 信号域,介导优越的抗肿瘤效应。
Nat Med. 2018 Mar;24(3):352-359. doi: 10.1038/nm.4478. Epub 2018 Feb 5.
7
Bacterial proteins that mediate the association of a defined subset of T cell receptor:CD4 complexes with class II MHC.介导特定子集的T细胞受体:CD4复合物与II类主要组织相容性复合体结合的细菌蛋白。
J Immunol. 1990 Feb 1;144(3):892-901.
8
Challenges and prospects of chimeric antigen receptor T cell therapy in solid tumors.嵌合抗原受体 T 细胞疗法在实体瘤中的挑战与展望。
Med Oncol. 2018 May 5;35(6):87. doi: 10.1007/s12032-018-1149-9.
9
Regulated Expansion and Survival of Chimeric Antigen Receptor-Modified T Cells Using Small Molecule-Dependent Inducible MyD88/CD40.使用依赖小分子的诱导型 MyD88/CD40 调控嵌合抗原受体修饰 T 细胞的扩增和存活。
Mol Ther. 2017 Sep 6;25(9):2176-2188. doi: 10.1016/j.ymthe.2017.06.014. Epub 2017 Jul 8.
10
Using Antigen-Specific B Cells to Combine Antibody and T Cell-Based Cancer Immunotherapy.利用抗原特异性 B 细胞将抗体和基于 T 细胞的癌症免疫疗法相结合。
Cancer Immunol Res. 2017 Sep;5(9):730-743. doi: 10.1158/2326-6066.CIR-16-0236. Epub 2017 Aug 4.

引用本文的文献

1
Optimised modular anti-FLAG CAR T cells for solid tumor therapy.用于实体瘤治疗的优化模块化抗FLAG嵌合抗原受体T细胞
Clin Transl Immunology. 2025 Aug 21;14(8):e70046. doi: 10.1002/cti2.70046. eCollection 2025.
2
Unraveling the gut microbiome's contribution to pancreatic ductal adenocarcinoma: mechanistic insights and therapeutic perspectives.揭开肠道微生物组对胰腺导管腺癌的贡献:机制见解和治疗观点。
Front Immunol. 2024 Jul 9;15:1434771. doi: 10.3389/fimmu.2024.1434771. eCollection 2024.
3
Unveiling the intratumoral microbiota within cancer landscapes.揭示癌症微环境中的肿瘤内微生物群。
iScience. 2024 May 3;27(6):109893. doi: 10.1016/j.isci.2024.109893. eCollection 2024 Jun 21.
4
Car T Cells in Solid Tumors: Overcoming Obstacles.实体瘤中的嵌合抗原受体T细胞:克服障碍
Int J Mol Sci. 2024 Apr 10;25(8):4170. doi: 10.3390/ijms25084170.
5
Superantigen-fused T cell engagers for tumor antigen-mediated robust T cell activation and tumor cell killing.用于肿瘤抗原介导的强大T细胞活化和肿瘤细胞杀伤的超抗原融合T细胞衔接器。
Mol Ther. 2024 Feb 7;32(2):490-502. doi: 10.1016/j.ymthe.2023.12.011. Epub 2023 Dec 14.
6
Enhancing co-stimulation of CAR T cells to improve treatment outcomes in solid cancers.增强嵌合抗原受体(CAR)T细胞的共刺激以改善实体癌的治疗效果。
Immunother Adv. 2021 Jul 31;1(1):ltab016. doi: 10.1093/immadv/ltab016. eCollection 2021 Jan.
7
Editorial: Understanding and Engineering Antibody-Superantigen Interactions.社论:理解与构建抗体-超抗原相互作用
Front Immunol. 2022 Feb 9;13:857339. doi: 10.3389/fimmu.2022.857339. eCollection 2022.
8
Enhancing Adoptive Cell Transfer with Combination BRAF-MEK and CDK4/6 Inhibitors in Melanoma.联合BRAF-MEK和CDK4/6抑制剂增强黑色素瘤的过继性细胞转移
Cancers (Basel). 2021 Dec 17;13(24):6342. doi: 10.3390/cancers13246342.
9
Superantigen Recognition and Interactions: Functions, Mechanisms and Applications.超抗原识别与相互作用:功能、机制与应用。
Front Immunol. 2021 Sep 20;12:731845. doi: 10.3389/fimmu.2021.731845. eCollection 2021.
10
Soluble Expression of Fc-Fused T Cell Receptors Allows Yielding Novel Bispecific T Cell Engagers.Fc融合T细胞受体的可溶性表达可产生新型双特异性T细胞衔接器。
Biomedicines. 2021 Jul 8;9(7):790. doi: 10.3390/biomedicines9070790.

本文引用的文献

1
CD40 Agonist Antibodies in Cancer Immunotherapy.CD40 激动剂抗体在癌症免疫治疗中的应用。
Annu Rev Med. 2020 Jan 27;71:47-58. doi: 10.1146/annurev-med-062518-045435. Epub 2019 Aug 14.
2
Selecting costimulatory domains for chimeric antigen receptors: functional and clinical considerations.选择嵌合抗原受体的共刺激结构域:功能及临床考量
Clin Transl Immunology. 2019 May 11;8(5):e1049. doi: 10.1002/cti2.1049. eCollection 2019.
3
CD137 (4-1BB) Signalosome: Complexity Is a Matter of TRAFs.CD137(4-1BB)信号小体:复杂性是 TRAFs 的问题。
Front Immunol. 2018 Nov 15;9:2618. doi: 10.3389/fimmu.2018.02618. eCollection 2018.
4
Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function.嵌合抗原受体信号的磷酸化蛋白质组学分析揭示了影响细胞功能的动力学和定量差异。
Sci Signal. 2018 Aug 21;11(544):eaat6753. doi: 10.1126/scisignal.aat6753.
5
Dendritic cell activation enhances anti-PD-1 mediated immunotherapy against glioblastoma.树突状细胞激活增强了抗程序性死亡蛋白 1 介导的胶质母细胞瘤免疫治疗效果。
Oncotarget. 2018 Apr 17;9(29):20681-20697. doi: 10.18632/oncotarget.25061.
6
Understanding the tumor immune microenvironment (TIME) for effective therapy.理解肿瘤免疫微环境(TIME)以实现有效的治疗。
Nat Med. 2018 May;24(5):541-550. doi: 10.1038/s41591-018-0014-x. Epub 2018 Apr 23.
7
CAR T Cells in Trials: Recent Achievements and Challenges that Remain in the Production of Modified T Cells for Clinical Applications.临床试验中的嵌合抗原受体 T 细胞:用于临床应用的修饰 T 细胞生产方面的最新成果和挑战。
Hum Gene Ther. 2018 May;29(5):559-568. doi: 10.1089/hum.2017.254. Epub 2018 Apr 5.
8
Activity of Mesothelin-Specific Chimeric Antigen Receptor T Cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial.嵌合抗原受体 T 细胞针对 1 期试验中胰腺癌细胞转移的间皮素特异性活性。
Gastroenterology. 2018 Jul;155(1):29-32. doi: 10.1053/j.gastro.2018.03.029. Epub 2018 Mar 20.
9
Chimeric antigen receptor T cells form nonclassical and potent immune synapses driving rapid cytotoxicity.嵌合抗原受体 T 细胞形成非经典且强效的免疫突触,从而驱动快速细胞毒性。
Proc Natl Acad Sci U S A. 2018 Feb 27;115(9):E2068-E2076. doi: 10.1073/pnas.1716266115. Epub 2018 Feb 12.
10
Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia.急性淋巴细胞白血病中CD19嵌合抗原受体疗法的长期随访
N Engl J Med. 2018 Feb 1;378(5):449-459. doi: 10.1056/NEJMoa1709919.

肠毒素可支持 CAR T 细胞对抗实体瘤。

Enterotoxins can support CAR T cells against solid tumors.

机构信息

Cancer Immunology Program, Peter MacCallum Cancer Center, Melbourne, VIC 3000, Australia.

Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, VIC 3000, Australia.

出版信息

Proc Natl Acad Sci U S A. 2019 Dec 10;116(50):25229-25235. doi: 10.1073/pnas.1904618116. Epub 2019 Nov 25.

DOI:10.1073/pnas.1904618116
PMID:31767744
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6911243/
Abstract

Responses of solid tumors to chimeric antigen receptor (CAR) T cell therapy are often minimal. This is potentially due to a lack of sustained activation and proliferation of CAR T cells when encountering antigen in a profoundly immunosuppressive tumor microenvironment. In this study, we investigate if inducing an interaction between CAR T cells and antigen-presenting cells (APCs) in lymphoid tissue, away from an immunosuppressive microenvironment, could enhance solid-tumor responses. We combined CAR T cell transfer with the bacterial enterotoxin staphylococcal enterotoxin-B (SEB), which naturally links a proportion of T cell receptor (TCR) Vβ subtypes to MHC-II, present on APCs. CAR T cell proliferation and function was significantly enhanced by SEB. Solid tumor-growth inhibition in mice was increased when CAR T cells were administered in combination with SEB. CAR T cell expansion in lymphoid tissue was demonstrated, and inhibition of lymphocyte egress from lymph nodes using FTY720 abrogated the benefit of SEB. We also demonstrate that a bispecific antibody, targeting a c-Myc tag on CAR T cells and cluster of differentiation 40 (CD40), could also enhance CAR T cell activity and mediate increased antitumor activity of CAR T cells. These model systems serve as proof-of-principle that facilitating the interaction of CAR T cells with APCs can enhance their ability to mediate antitumor activity.

摘要

嵌合抗原受体 (CAR) T 细胞疗法对实体瘤的反应通常很小。这可能是由于 CAR T 细胞在遇到抗原时,在深度免疫抑制的肿瘤微环境中缺乏持续的激活和增殖。在这项研究中,我们研究了是否可以通过在远离免疫抑制微环境的淋巴组织中诱导 CAR T 细胞与抗原呈递细胞 (APC) 之间的相互作用来增强实体瘤的反应。我们将 CAR T 细胞转移与细菌肠毒素金黄色葡萄球菌肠毒素-B(SEB)结合使用,SEB 可将 TCR Vβ 亚类的一部分与 APC 上的 MHC-II 天然连接。SEB 显著增强了 CAR T 细胞的增殖和功能。当 CAR T 细胞与 SEB 联合给药时,可增加小鼠实体瘤的生长抑制。证明了在淋巴组织中 CAR T 细胞的扩增,并使用 FTY720 抑制淋巴细胞从淋巴结中迁出,从而消除了 SEB 的作用。我们还证明,一种针对 CAR T 细胞上的 c-Myc 标记物和分化抗原 40(CD40)的双特异性抗体也可以增强 CAR T 细胞的活性,并介导 CAR T 细胞抗肿瘤活性的增加。这些模型系统证明了促进 CAR T 细胞与 APC 相互作用可以增强它们介导抗肿瘤活性的能力。